Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science focusing critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company's goal is the development of governmentally approved pharmaceuticals, including the aforementioned CS-TATI1, CS-S/BCC-1, and patented neurological therapy under study or development. The Company has two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV. The Company has partnered with propagators and laboratories for extractions, analytical development and clinical trial implementation.